Aktis Oncology Partners with Eli Lilly in $1.1 Billion Cancer Therapy Deal

May 21, 2024, 01:10 PM

Aktis Oncology announced on Tuesday a collaboration with Eli Lilly ($LLY) to develop novel anticancer radiopharmaceuticals. The partnership makes Aktis eligible for milestone payments of up to $1.1 billion and royalties on sales. The deal includes a $60 million upfront payment. This collaboration follows Eli Lilly's acquisition of Point Biopharma for $1.4 billion last year, further deepening Lilly's investment in radiopharmaceuticals.